– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m.
PDT –
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis,
Inc. (NASDAQ: EXEL) announced today that its first quarter 2019
financial results will be released on Wednesday, May 1, 2019 after the
markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call and webcast to discuss the results and
provide a general business update. Access to the event is available via
the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 4774486 to join
by phone.
A telephone replay will be available until 8:00 p.m. EDT on May 3, 2019.
Access numbers for the telephone replay are: 855-859-2056 (domestic) and
404-537-3406 (international); the passcode is 4774486. A webcast replay
will also be archived on www.exelixis.com
for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. Our discovery efforts
have resulted in four approved products, CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib)
and MINNEBRO™ (esaxerenone), and we have entered into partnerships with
leading pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed products and
collaborations, we are committed to prudently reinvesting in our
business to maximize the potential of our pipeline. We are supplementing
our existing therapeutic assets with targeted business development
activities and internal drug discovery – all to deliver the next
generation of Exelixis medicines and help patients recover stronger and
live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized companies.
For more information about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc on
Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks. MINNEBRO is a Japanese trademark.
Contacts
Susan Hubbard
Executive Vice President,
Public
Affairs & Investor Relations
Exelixis, Inc.
650-837-8194
shubbard@exelixis.com